2026年3月最新《新锐期刊分区表》数据已更新,欢迎查询使用。如果您对期刊系统有任何需求或者问题,欢迎反馈给我们。
![]() |
体验更多LetPub AI科研工具 >> | |
| |
| 基本信息 | 登录收藏 | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字![]() | ANTI-CANCER DRUGS ANTI-CANCER DRUG (此期刊被最新的JCR期刊SCIE收录) LetPub评分 5.7
56人评分
我要评分
声誉 6.5 影响力 4.4 速度 8.7 | |||||||||||||||||||||||||||||||
| 期刊ISSN | 0959-4973 | 安装APP,查看期刊最新消息
| ||||||||||||||||||||||||||||||
| E-ISSN | 1473-5741 | |||||||||||||||||||||||||||||||
| 2024-2025最新影响因子 (数据来源于搜索引擎) | 2.2 点击查看影响因子趋势图 | |||||||||||||||||||||||||||||||
| 实时影响因子 | 截止2026年5月06日:2.02 | |||||||||||||||||||||||||||||||
| 2024-2025自引率 | 4.5%点击查看自引率趋势图 | |||||||||||||||||||||||||||||||
| 五年影响因子 | 1.9 | |||||||||||||||||||||||||||||||
| JCI期刊引文指标 | 0.6 | |||||||||||||||||||||||||||||||
| h-index | 88 | |||||||||||||||||||||||||||||||
| CiteScore ( 2025年最新版) |
| |||||||||||||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||||||||||||
| 期刊官方网站 | http://journals.lww.com/anti-cancerdrugs/pages/default.aspx | |||||||||||||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||||||||||||
| 期刊投稿网址 | https://www.editorialmanager.com/ACD | |||||||||||||||||||||||||||||||
| 该期刊中国学者近期发文 - New | Multimodal treatment with thiotepa, bevacizumab, teniposide, and tunlametinib in a patient with neurofibromatosis type 1-associated oligodendroglioma: a rare case report Author: Zhou, Shizhen; Chen, Yanfei; Gao, Guoliang; Pan, Xueqiang; Sun, Peng; Tao, Rongjie Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 4, pp. -. DOI: 10.1097/CAD.0000000000001786 Comparative efficacy and safety of S-1 plus oxaliplatin with sintilimab vs. paclitaxel-S-1-oxaliplatin and docetaxel-oxaliplatin-5-fluorouracil as first-line therapy for advanced gastric cancer Author: Wang, Yicong; Ma, Bingyang; Zhang, Chenguang; Wang, Yuwen; Pan, Ting; Zhao, Chunlong; Cai, Baojia; Yu, Pengjie; Guo, Bin; Ma, Jinfu Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 4, pp. 253-264. DOI: 10.1097/CAD.0000000000001782 EP4 influences bortezomib resistance in multiple myeloma by modulating endoplasmic reticulum stress via the phosphatidylinositol 3-kinase/protein kinase B pathway Author: Shi, Tengfei; Chen, Yao; Liu, Zhiqiang; Liu, Aichun Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 4, pp. 280-296. DOI: 10.1097/CAD.0000000000001792 Initial stage analysis of tislelizumab in combination with chemotherapy for patients with advanced HIV-positive non-small-cell lung cancer: a comparative clinical trial Author: Quan, Yaping; Li, Hao; Liang, Zhengjie; Shen, Jie; Hu, Yong Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 4, pp. 272-279. DOI: 10.1097/CAD.0000000000001784 | |||||||||||||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足ANTI-CANCER DRUGS的语言要求,还能让ANTI-CANCER DRUGS编辑和审稿人得到更好的审稿体验,让稿件最大限度地被ANTI-CANCER DRUGS编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢(2篇) 。
提交文稿 | |||||||||||||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||||||||||||
| 通讯方式 | LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, USA, PA, 19106-3621 | |||||||||||||||||||||||||||||||
| 出版商 | Lippincott Williams and Wilkins Ltd. | |||||||||||||||||||||||||||||||
| 涉及的研究方向 | 医学-药学 | |||||||||||||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||||||||||||
| 出版周期 | Monthly | |||||||||||||||||||||||||||||||
| 出版年份 | 1990 | |||||||||||||||||||||||||||||||
| 年文章数 | 121点击查看年文章数趋势图 | |||||||||||||||||||||||||||||||
| Gold OA文章占比 | 21.63% | |||||||||||||||||||||||||||||||
| 研究类文章占比: 文章 ÷(文章 + 综述) | 96.69% | |||||||||||||||||||||||||||||||
| WOS期刊JCR分区 ( 2024-2025年最新版) | WOS分区等级:3区
| |||||||||||||||||||||||||||||||
| 期刊分区表预警名单 | 2026年03月发布的新锐学术版:不在预警名单中 2025年03月发布的2025版:不在预警名单中 2024年02月发布的2024版:不在预警名单中 2023年01月发布的2023版:不在预警名单中 2021年12月发布的2021版:不在预警名单中 2020年12月发布的2020版:不在预警名单中 | |||||||||||||||||||||||||||||||
| 《新锐期刊分区表》 ( 2026年3月发布) | 点击查看期刊分区表趋势图
| |||||||||||||||||||||||||||||||
| 期刊分区表 ( 2025年3月升级版) |
| |||||||||||||||||||||||||||||||
| 期刊分区表 ( 2023年12月旧的升级版) |
| |||||||||||||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0959-4973%5BISSN%5D | |||||||||||||||||||||||||||||||
| 平均审稿速度 | 网友分享经验: 偏慢,4-8周 | |||||||||||||||||||||||||||||||
| 平均录用比例 | 网友分享经验: 容易 | |||||||||||||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)后论文在ANTI-CANCER DRUGS顺利发表。
快看看作者怎么说吧:服务好评 论文致谢(2篇) 。 提交文稿 | |||||||||||||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Multimodal treatment with thiotepa, bevacizumab, teniposide, and tunlametinib in a patient with neurofibromatosis type 1-associated oligodendroglioma: a rare case report Author: Zhou, Shizhen; Chen, Yanfei; Gao, Guoliang; Pan, Xueqiang; Sun, Peng; Tao, Rongjie Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 4, pp. -. DOI: 10.1097/CAD.0000000000001786 PubMed DOI |
| 2. | Comparative efficacy and safety of S-1 plus oxaliplatin with sintilimab vs. paclitaxel-S-1-oxaliplatin and docetaxel-oxaliplatin-5-fluorouracil as first-line therapy for advanced gastric cancer Author: Wang, Yicong; Ma, Bingyang; Zhang, Chenguang; Wang, Yuwen; Pan, Ting; Zhao, Chunlong; Cai, Baojia; Yu, Pengjie; Guo, Bin; Ma, Jinfu Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 4, pp. 253-264. DOI: 10.1097/CAD.0000000000001782 PubMed DOI |
| 3. | EP4 influences bortezomib resistance in multiple myeloma by modulating endoplasmic reticulum stress via the phosphatidylinositol 3-kinase/protein kinase B pathway Author: Shi, Tengfei; Chen, Yao; Liu, Zhiqiang; Liu, Aichun Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 4, pp. 280-296. DOI: 10.1097/CAD.0000000000001792 PubMed DOI |
| 4. | Initial stage analysis of tislelizumab in combination with chemotherapy for patients with advanced HIV-positive non-small-cell lung cancer: a comparative clinical trial Author: Quan, Yaping; Li, Hao; Liang, Zhengjie; Shen, Jie; Hu, Yong Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 4, pp. 272-279. DOI: 10.1097/CAD.0000000000001784 PubMed DOI |
| 5. | Identification of uridine phosphatase 1 as a potential therapeutic target in gastric cancer by integrated bioinformatics analysis and experimental validation Author: Wang, Yongfeng; Feng, Yichen; Zhu, Chengzhang; Guan, Ling; Wang, Shengfeng; Zou, Anqi; Yu, Miao; Yuan, Yuan; Cai, Hui Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 3, pp. 217-237. DOI: 10.1097/CAD.0000000000001745 PubMed DOI |
| 6. | Activation of the caspase-1/gasdermin D pathway via α-linolenic acid-mediated GPR120 signaling induces pyroptosis and suppresses ovarian cancer tumor growth Author: Sun, Shijie; Qian, Li Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 3, pp. 190-203. DOI: 10.1097/CAD.0000000000001789 PubMed DOI |
| 7. | Apatinib triggers ferroptosis in gastric cancer via HDAC1/HIF1α/CA9 signaling axis Author: Meng, Lijuan; Cao, Lei; Lu, Yueyao; Yang, Lixin; Zhu, Weiyou Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 3, pp. 169-180. DOI: 10.1097/CAD.0000000000001776 PubMed DOI |
| 8. | Histone lactylation promoted colorectal cancer progression by enhancing tumor necrosis factor transcription and served as a diagnostic biomarker Author: Li, Shiyang; Shi, Xiufang; Zhou, Xiaoyue Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 3, pp. -. DOI: 10.1097/CAD.0000000000001771 PubMed DOI |
| 9. | Clinical importance of the interactions between the TGF-β1/SMAD and NF-κB pathways in colorectal cancer and the study of the synergistic regulatory mechanism of the STAT3-mediated pathway Author: Chao, Huang; Liu, Haosheng; Shen, Weizeng Journal: ANTI-CANCER DRUGS. 2026; Vol. 37, Issue 3, pp. 204-216. DOI: 10.1097/CAD.0000000000001802 PubMed DOI |
| 10. | Response to PARP inhibitor in EGFR-tyrosine kinase inhibitor-resistant metastatic lung adenocarcinoma with germline PALB2 mutation Author: Zhu, Chao; Xu, Peng; Li, Lantao; Wei, Hongmei Journal: ANTI-CANCER DRUGS. 2025; Vol. 36, Issue 6, pp. 518-520. DOI: 10.1097/CAD.0000000000001712 PubMed DOI |
|
|
投稿状态统计: 我要评分: | ||||||||||||||||
| 投稿前担心稿件结构或语言不够规范?试试稿件自查工具,一键检测 >> | ||||||||||||||||
|
||||||||||||||||
同领域作者分享投稿经验:共188条 |
||||||||||||||||
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2026 中国: LetPub上海 网站备案号:沪ICP备10217908号-1
沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)
增值电信业务经营许可证:沪B2-20211595 网络文化经营许可证:沪网文[2023]2004-152号
礼翰商务信息咨询(上海)有限公司 办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室